初治滤泡性淋巴瘤患者接受CHOP联合利妥昔单抗或CHOP联合碘-131托西莫单抗治疗后的持续优异结局:III期随机研究SWOG-S0016的长期随访
SWOG-S0016是一项III期随机研究,2001年至2008年入组531例初治滤泡性淋巴瘤患者,随机接受六周期R-CHOP或CHOP-RIT。中位随访10.3年,CHOP-RIT组10年无进展生存优于R-CHOP组(56%对42%,P=0.01),但10年总生存无差异(75%对81%,P=0.13)。
要点
- CHOP-RIT组10年无进展生存显著优于R-CHOP组(56%对42%,P=0.01)。
- 两组10年总生存无显著差异(CHOP-RIT 75%对R-CHOP 81%,P=0.13)。
- CHOP-RIT组继发MDS/AML的10年累积死亡发生率高于R-CHOP组(4%对0.9%,P=0.02)。
核心结论
- 鉴于这些优异结局,在替代方法的长期随访证明优效之前,免疫化疗应继续作为高危滤泡性淋巴瘤患者的标准诱导方案。
研究设计与样本
- SWOG S0016是一项III期随机研究,2001年至2008年入组531例初治滤泡性淋巴瘤患者,随机接受六周期R-CHOP或六周期CHOP-RIT。
- 入组患者为晚期疾病(大块II期、III期或IV期),病理分级为1、2或3级。
主要发现
- 中位随访10.3年,全部患者的10年无进展生存和总生存估计分别为49%和78%。
- CHOP-RIT组10年无进展生存显著优于R-CHOP组(56%对42%,P=0.01)。
- 两组10年总生存无差异(CHOP-RIT 75%对R-CHOP 81%,P=0.13)。
- 两组第二恶性肿瘤发生率无显著差异(CHOP-RIT 15.1%对R-CHOP 16.1%,P=0.81),MDS或AML发生率也无显著差异(CHOP-RIT 4.9%对R-CHOP 1.8%,P=0.058)。
- 第二恶性肿瘤所致死亡的10年累积发生率无差异(CHOP-RIT 7.1%对R-CHOP 3.2%,P=0.16),但MDS或AML所致死亡的累积发生率CHOP-RIT组高于R-CHOP组(4%对0.9%,P=0.02)。
临床怎么用
- 作者认为,在替代方法的长期随访证明优效之前,免疫化疗应继续作为高危滤泡性淋巴瘤患者的标准诱导方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose SWOG S0016 was a phase III randomized study that compared the safety and efficacy of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) with CHOP-RIT (CHOP followed by consolidation with iodine-133-tositumomab radioimmunotherapy) for previously untreated patients with follicular lymphoma. Understanding the long-term outcome of patients provides a benchmark for novel treatment regimens for FL. Patients and Methods Between 2001 and 2008, 531 previously untreated patients with FL were randomly assigned to receive either six cycles of R-CHOP or six cycles of CHOP-RIT. Patients with advanced-stage disease (bulky stage II, III, or IV) of any pathologic grade (1, 2, or 3) were eligible. Results After a median follow-up of 10.3 years, 10-year estimates of progression-free and overall survival were 49% and 78% among all patients, respectively. Patients in the CHOP-RIT arm had significantly better 10-year progression-free survival compared with patients in the R-CHOP arm (56% v 42%; P = .01), but 10-year overall survival was not different between the two arms (75% v 81%; P = .13). There was no significant difference between the CHOP-RIT and R-CHOP arms in regard to incidence of second malignancies (15.1% v 16.1%; P = .81) or myelodysplastic syndrome or acute myeloid leukemia (4.9% v 1.8%; P = .058). The estimated 10-year cumulative incidences of death resulting from second malignancies were not different (7.1% v 3.2%; P = .16), but cumulative incidence of death resulting from myelodysplastic syndrome or acute myeloid leukemia was higher in the CHOP-RIT arm compared with the R-CHOP arm (4% v 0.9%; P = .02). Conclusion Given these outstanding outcomes, immunochemotherapy should remain the standard induction approach for patients with high-risk FL until long-term follow-up of alternative approaches demonstrates superiority.
引用
- Shadman M, Li H, Rimsza L, et al. Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016. J Clin Oncol. 2018. PMID: 29356608. doi:10.1200/JCO.2017.74.5083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。